KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Castle Biosciences (CSTL) Non-Current Receivables (2018 - 2026)

Castle Biosciences' Non-Current Receivables history spans 8 years, with the latest figure at $1.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Receivables rose 104.58% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 104.58% increase, with the full-year FY2025 number at $1.9 million, up 104.58% from a year prior.
  • Non-Current Receivables hit $1.9 million in Q4 2025 for Castle Biosciences, down from $2.0 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for CSTL hit a ceiling of $2.0 million in Q3 2025 and a floor of $918000.0 in Q4 2024.
  • Historically, Non-Current Receivables has averaged $1.3 million across 5 years, with a median of $1.2 million in 2023.
  • Biggest five-year swings in Non-Current Receivables: decreased 22.92% in 2024 and later soared 104.58% in 2025.
  • Tracing CSTL's Non-Current Receivables over 5 years: stood at $1.3 million in 2021, then fell by 16.9% to $1.1 million in 2022, then increased by 9.57% to $1.2 million in 2023, then decreased by 22.92% to $918000.0 in 2024, then surged by 104.58% to $1.9 million in 2025.
  • Business Quant data shows Non-Current Receivables for CSTL at $1.9 million in Q4 2025, $2.0 million in Q3 2025, and $1.1 million in Q2 2025.